An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma continues to show unprecedented and durable results with few side effects.
http://www.biosciencetechnology.com/news/2012/12/ibrutinib-has-unprecedented-impact-mantle-cell-lymphoma
http://www.biosciencetechnology.com/news/2012/12/ibrutinib-has-unprecedented-impact-mantle-cell-lymphoma
No comments:
Post a Comment